Plasma Sphingolipids are Associated with Gait Parameters in the Mayo Clinic Study of Aging

Alexandra M.V. Wennberg, Marissa J. Schafer, Nathan K LeBrasseur, Rodolfo Savica, Hai H. Bui, Clinton E. Hagen, John H. Hollman, Ronald Carl Petersen, Michelle M Mielke

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background Disrupted gait has been associated with an increased risk of frailty, disability, and death, but the causal molecular pathways are not well understood. Sphingolipids, including ceramides, are associated with multiple age-related diseases. Ceramides promote atrophy, necrosis, and proteolysis in cellular and animal models, and ceramide C16:0 levels are negatively correlated with muscle mass in men. However, there is a paucity of evidence examining sphingolipids and physical function. Methods We examined the cross-sectional association between plasma ceramides, sphingosine-1-phosphate (S1P), and ceramide/S1P ratios and gait, a robust measure of physical function, in 340 clinically normal participants aged 70 years and older enrolled in the Mayo Clinic Study of Aging. GAITRite® instrumentation was used to measure gait speed, cadence, step width, double support time, and intra-individual stride time variability. Based on previous studies, we hypothesized that higher plasma levels of ceramide C16:0 would be associated with worse gait. Results Multivariable adjusted linear regression models revealed that higher levels of ceramide C16:0 were associated with slower gait speed, decreased cadence, and increased double support time. Conclusions These results suggest an association between plasma ceramide C16:0 and physical function. Longitudinal studies are needed to determine whether elevated ceramide C16:0 can be utilized as a prognostic marker for functional decline.

Original languageEnglish (US)
Pages (from-to)960-965
Number of pages6
JournalJournals of Gerontology - Series A Biological Sciences and Medical Sciences
Volume73
Issue number7
DOIs
StatePublished - Jun 14 2018

Fingerprint

Sphingolipids
Gait
Ceramides
Linear Models
Proteolysis
Atrophy
Longitudinal Studies
Necrosis
Animal Models
N-palmitoylsphingosine
Muscles

Keywords

  • Atrophy
  • Ceramides
  • Functionality

ASJC Scopus subject areas

  • Aging
  • Geriatrics and Gerontology

Cite this

Plasma Sphingolipids are Associated with Gait Parameters in the Mayo Clinic Study of Aging. / Wennberg, Alexandra M.V.; Schafer, Marissa J.; LeBrasseur, Nathan K; Savica, Rodolfo; Bui, Hai H.; Hagen, Clinton E.; Hollman, John H.; Petersen, Ronald Carl; Mielke, Michelle M.

In: Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 73, No. 7, 14.06.2018, p. 960-965.

Research output: Contribution to journalArticle

@article{f1e45ced43724c88a6378cb0d3506219,
title = "Plasma Sphingolipids are Associated with Gait Parameters in the Mayo Clinic Study of Aging",
abstract = "Background Disrupted gait has been associated with an increased risk of frailty, disability, and death, but the causal molecular pathways are not well understood. Sphingolipids, including ceramides, are associated with multiple age-related diseases. Ceramides promote atrophy, necrosis, and proteolysis in cellular and animal models, and ceramide C16:0 levels are negatively correlated with muscle mass in men. However, there is a paucity of evidence examining sphingolipids and physical function. Methods We examined the cross-sectional association between plasma ceramides, sphingosine-1-phosphate (S1P), and ceramide/S1P ratios and gait, a robust measure of physical function, in 340 clinically normal participants aged 70 years and older enrolled in the Mayo Clinic Study of Aging. GAITRite{\circledR} instrumentation was used to measure gait speed, cadence, step width, double support time, and intra-individual stride time variability. Based on previous studies, we hypothesized that higher plasma levels of ceramide C16:0 would be associated with worse gait. Results Multivariable adjusted linear regression models revealed that higher levels of ceramide C16:0 were associated with slower gait speed, decreased cadence, and increased double support time. Conclusions These results suggest an association between plasma ceramide C16:0 and physical function. Longitudinal studies are needed to determine whether elevated ceramide C16:0 can be utilized as a prognostic marker for functional decline.",
keywords = "Atrophy, Ceramides, Functionality",
author = "Wennberg, {Alexandra M.V.} and Schafer, {Marissa J.} and LeBrasseur, {Nathan K} and Rodolfo Savica and Bui, {Hai H.} and Hagen, {Clinton E.} and Hollman, {John H.} and Petersen, {Ronald Carl} and Mielke, {Michelle M}",
year = "2018",
month = "6",
day = "14",
doi = "10.1093/gerona/glx139",
language = "English (US)",
volume = "73",
pages = "960--965",
journal = "Journals of Gerontology - Series A Biological Sciences and Medical Sciences",
issn = "1079-5006",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Plasma Sphingolipids are Associated with Gait Parameters in the Mayo Clinic Study of Aging

AU - Wennberg, Alexandra M.V.

AU - Schafer, Marissa J.

AU - LeBrasseur, Nathan K

AU - Savica, Rodolfo

AU - Bui, Hai H.

AU - Hagen, Clinton E.

AU - Hollman, John H.

AU - Petersen, Ronald Carl

AU - Mielke, Michelle M

PY - 2018/6/14

Y1 - 2018/6/14

N2 - Background Disrupted gait has been associated with an increased risk of frailty, disability, and death, but the causal molecular pathways are not well understood. Sphingolipids, including ceramides, are associated with multiple age-related diseases. Ceramides promote atrophy, necrosis, and proteolysis in cellular and animal models, and ceramide C16:0 levels are negatively correlated with muscle mass in men. However, there is a paucity of evidence examining sphingolipids and physical function. Methods We examined the cross-sectional association between plasma ceramides, sphingosine-1-phosphate (S1P), and ceramide/S1P ratios and gait, a robust measure of physical function, in 340 clinically normal participants aged 70 years and older enrolled in the Mayo Clinic Study of Aging. GAITRite® instrumentation was used to measure gait speed, cadence, step width, double support time, and intra-individual stride time variability. Based on previous studies, we hypothesized that higher plasma levels of ceramide C16:0 would be associated with worse gait. Results Multivariable adjusted linear regression models revealed that higher levels of ceramide C16:0 were associated with slower gait speed, decreased cadence, and increased double support time. Conclusions These results suggest an association between plasma ceramide C16:0 and physical function. Longitudinal studies are needed to determine whether elevated ceramide C16:0 can be utilized as a prognostic marker for functional decline.

AB - Background Disrupted gait has been associated with an increased risk of frailty, disability, and death, but the causal molecular pathways are not well understood. Sphingolipids, including ceramides, are associated with multiple age-related diseases. Ceramides promote atrophy, necrosis, and proteolysis in cellular and animal models, and ceramide C16:0 levels are negatively correlated with muscle mass in men. However, there is a paucity of evidence examining sphingolipids and physical function. Methods We examined the cross-sectional association between plasma ceramides, sphingosine-1-phosphate (S1P), and ceramide/S1P ratios and gait, a robust measure of physical function, in 340 clinically normal participants aged 70 years and older enrolled in the Mayo Clinic Study of Aging. GAITRite® instrumentation was used to measure gait speed, cadence, step width, double support time, and intra-individual stride time variability. Based on previous studies, we hypothesized that higher plasma levels of ceramide C16:0 would be associated with worse gait. Results Multivariable adjusted linear regression models revealed that higher levels of ceramide C16:0 were associated with slower gait speed, decreased cadence, and increased double support time. Conclusions These results suggest an association between plasma ceramide C16:0 and physical function. Longitudinal studies are needed to determine whether elevated ceramide C16:0 can be utilized as a prognostic marker for functional decline.

KW - Atrophy

KW - Ceramides

KW - Functionality

UR - http://www.scopus.com/inward/record.url?scp=85048753380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048753380&partnerID=8YFLogxK

U2 - 10.1093/gerona/glx139

DO - 10.1093/gerona/glx139

M3 - Article

C2 - 28977376

AN - SCOPUS:85048753380

VL - 73

SP - 960

EP - 965

JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences

SN - 1079-5006

IS - 7

ER -